Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhanced Adjuvant Therapy for Glioblastoma
NCT06936046Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, cadonilimab in glioblastoma (GBM), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Jan 2025; status: recruiting.
02
Drugs
ivonescimabcadonilimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06936046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06936046.